Navigation Links
Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value
Date:2/26/2009

cinod's efficacy and achieves target product profile

In 2008, NicOx successfully completed the phase 3 clinical program for naproxcinod in patients with OA of the knee (the 301 and 302 studies) and hip (the 303 study), with all three studies achieving highly statistically significant results on all three co-primary efficacy endpoints (the WOMAC(TM) pain subscale, WOMAC(TM) function subscale and subject's overall rating of disease status), as well as good overall safety and tolerability.

    - In July, the top-line results of the 52-week safety extension of the
      301 study were reported, which revealed no unexpected safety findings
      and showed a good overall long term safety for both doses of
      naproxcinod.

    - The 302 study reported top-line results in 1020 knee-OA
      patients in September 2008. In addition to meeting the three co-primary
      endpoints at 13 weeks (p<0.001), both doses of naproxcinod (750 mg and
      375 bid) were statistically non-inferior to naproxen 500 mg bid at 26
      weeks, in terms of the mean change from baseline in the WOMAC(TM) pain
      and function subscales.

    - Top-line results from the 303 study in 810 patients with OA
      of the hip were reported in November. Naproxcinod 750 mg bid met all
      three co-primary efficacy endpoints with high statistical significance
      (p<0.001).

During 2008, NicOx successfully completed an extensive database describing naproxcinod's blood pressure profile in more than 3,000 patients, using Office Blood Pressure Measurements (OBPM) and Ambulatory Blood Pressure Monitoring (ABPM).

Naproxcinod shows positive blood pressure results in phase 3 pooled analysis

In December 2008, NicOx announced the top-line results of the pooled blood pressure analysis from the phase 3 program (304). OBPM measurements were taken in a rigorous and standardized manner in each of the pha
'/>"/>

SOURCE NicOx
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Arpida Announces Full Year 2008 Financial Results
2. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
3. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
4. American Oriental Bioengineering, Inc. to Report Fourth Quarter and Full Year 2008 Financial Results on March 9, 2009
5. Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent
6. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
7. CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results
8. Human Genome Sciences to Sponsor Conference Call to Discuss Full Year 2008 Financial Results
9. Adolor Corporation to Host Investor Conference Call to Report 2008 Financials and Provide an Update on the Launch of ENTEREG(R) (alvimopan)
10. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
11. Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 The overall research objective ... sequencing trends and use. Most researchers outsource NGS ... to increase within the next 12 months. Data ... for purchasing sequencing instruments. Disease-related research is the ... RNA-Seq continues to surge, with half of the ...
(Date:9/30/2014)... Rainbow Scientific, Inc. (RSI), a North ... an online store to add customer convenience in ... and manufactured by Biological Industries, Inc. , Products ... Nutristem® serum-free, xeno-free reagents for human mesenchymal stem ... culture. , The online store also offers ...
(Date:9/30/2014)... Canada (PRWEB) September 30, 2014 Back in ... on 500 square feet. per employee, which included space for ... back then.” says Jeff Howell, partner at Nidea Corporate ... firm in Toronto. “By the year 2000, however, 250 ... now seeing that number come down to 175 to 225 ...
(Date:9/29/2014)... in Iraq and Afghanistan, more than 300,000 soldiers have ... caused by exposure to bomb blasts and in ... of traumatic brain injury can range from the mild, ... impairments in memory and cognition. , Since 2007, ... importance and complexity of this problem, and has made ...
Breaking Biology Technology:Global Next-generation Sequencing Trends 2Rainbow Scientific, Inc. opens online store for state-of-the-art stem cell culture and cytogenetic reagents 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 3Modeling shockwaves through the brain 2Modeling shockwaves through the brain 3Modeling shockwaves through the brain 4
... Va., Oct. 16 Varian Medical,Systems (NYSE: ... version of its market-leading,VariSeed(TM) brachytherapy seed planning ... allow greater visibility of the,treatment. "The ... the positions of,individual seeds in permanent seed ...
... Ranked 11th of the ,200 Best Small Companies In ... Inc.,(Nasdaq: ABAX ), a medical products company manufacturing ... chairman and chief executive officer, was named "Entrepreneur of,the ... issue. Also in that,issue, Abaxis was ranked eleventh of ...
... Novartis Takes Top Spot, Previously Held by GlaxoSmithKline ... 16 Thomson,Scientific, part of The Thomson Corporation ... of information solutions to the worldwide research and,business ... recent,quarterly review of scientific literature on drugs and ...
Cached Biology Technology:Varian Medical Systems Introduces New and Improved VariSeed(TM) 8.0 Software for Permanent Seed Prostate Brachytherapy Treatments 2Varian Medical Systems Introduces New and Improved VariSeed(TM) 8.0 Software for Permanent Seed Prostate Brachytherapy Treatments 3Abaxis CEO Clint Severson Named 'Entrepreneur of the Year' by Forbes Magazine 2Thomson Scientific Publishes 'Who Is Making The Biggest Splash?' - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007 2Thomson Scientific Publishes 'Who Is Making The Biggest Splash?' - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007 3
(Date:9/30/2014)... Journal of Medicine reports positive results of a ... the subset of lung cancer marked by rearrangement of ... patients with advanced non-small cell lung cancer testing positive ... percent, with 3 complete responses and 33 partial responses. ... the disease to resume its growth after being slowed ...
(Date:9/30/2014)... is available in German . ... the most expensive foods in the world. Because they grow ... But the distinctive smell of truffles is not only of ... under the direction of the Goethe University Frankfurt have discovered ... soil bacteria which are trapped inside truffle fruiting bodies. , ...
(Date:9/30/2014)... to using marijuana, new research, involving mice and published ... Journal of Leukocyte Biology , suggests that just ... should. That,s because a team of Italian scientists have ... long-term damage to the immune system. This damage may ... as multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis ...
Breaking Biology News(10 mins):NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2On the trail of the truffle flavor 2Adolescent exposure to thc may cause immune systems to go up in smoke 2
... An international team of researchers, including a University of ... giant cephalopod fossils discovered two years ago in England contain ... the melanin found in the ink sac of a modern-day ... May 21 edition of the journal Proceedings of the ...
... Stanford University School of Medicine, Stanford, California, has been honored ... her years of volunteer service to ASM. "For as long ... Baron has been the heart and soul of my profession," ... Development, North America, for bioMrieux, Inc., Durham, NC. ...
... by financial strategists to determine what shares to purchase to ... diversified portfolio of another kind -- land to be set ... Instead of plugging into the formula the data for ... Amy Ando and agricultural economist Mindy Mallory used the historical ...
Cached Biology News:Squid ink from Jurassic period identical to modern squid ink, U.Va. study shows 2Squid ink from Jurassic period identical to modern squid ink, U.Va. study shows 3The American Society for Microbiology honors Ellen Jo Baron 2The American Society for Microbiology honors Ellen Jo Baron 3Financial tool considered climate change uncertainty to select land for conservation 2Financial tool considered climate change uncertainty to select land for conservation 3
... is an aqueous-based mounting medium designed ... sections. Gel/Mount is especially recommended when ... or FluoroBlue. It can also be ... as fluorescein (FITC), Rhodamine (TMRITC) and ...
... - Fixation medium Reagent B - Permeabilisation ... fixing cells in suspension with Reagent A ... B. This procedure gives antibodies access to ... characteristics of the cells intact. Specific formulations ...
...
Collected from calves that are 10 days old or less. Sterile, cell culture tested, US Origin...
Biology Products: